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INTRODUCTION 
 
  Human fight against emerging dreaded diseases like Tuberculosis, 
Syphilis and Leprosy and Malignancies is continuing for decades. Now we 
face still more challenging, disastrous and dangerous disease, AIDS, with its 
capability of destroying one’s own immune mechanism. Destroying all 
boundaries among the nations, races and religions, this disease spreads in a 
very high speed. 
 
  Emerging as a global pandemic, this killer disease infected tens of 
millions of patients in less than three decades and orphaned more than ten 
million children in the same period. The HIV epidemic continues to increase 
at an alarming rate. The countries with large population and areas of poverty 
contribute the bulk of the cases. 
 
  Acquired immunodeficiency syndrome (AIDS) is an infectious 
disease caused by a retrovirus, the Human Immunodeficiency Virus (HIV). 
This syndrome is characterized by a gradual decrease in circulating CD4 + T 
lymphocytes and subsequent development of various opportunistic 
infections and neoplasia. 
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  At present, an estimated population of 40 million adults and  
3 million children are infected with HIV, and 25 million people had already died of 
AIDS. There are 13000 new infections everyday and current trends suggest that there 
may be 90-110 million people will be affected by the end of this decade. 
 
World estimates of the HIV & AIDS epidemics at the end of 2005 
  Estimate* Range* 
Total 40.3 36.7-45.3 
Adults 38.0 34.5-
42.6 
Women 17.5 16.2-19.3 
Number of people living with 
HIV/AIDS in 2005 
Children 2.3 2.1-2.8 
  Estimate* Range* 
Total 4.9 4.3-6.6 
Adults 4.2 3.6-5.8 
People newly infected with HIV in 
2005 
Children 0.70 0.63-0.82 
  Estimate* Range* 
Total 3.1 2.8-3.6 
Adults 2.6 2.3-2.9 
AIDS deaths in 2005 
Children 0.57 0.51-0.67 
 
* millions 
•   
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       Because of the 100% mortality rate, the worldwide distribution and 
the enormous social stigma attached to the disease, AIDS, unlike any other 
past epidemic, requires mobilization of national resources, the support of 
community leaders and public education regarding safe sex practices, 
training of health care personnel and help from industry in developing 
vaccines and newer antiviral drugs. 
 
  The role of the ophthalmologist in the diagnosis of AIDS is 
becoming increasingly important. Not only does the eye reflects systemic 
disease, but ocular involvement may often precede systemic manifestations. 
In the AIDS patient, the ophthalmologist thus has an opportunity to make 
not only a sight saving, but also a life saving diagnosis of disseminated 
opportunistic infections. 
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EPIDEMIOLOGY AND HISTORY 
 
 AIDS was first recognized in the united states in the summer of 1981, 
when the Centre for Disease Control and prevention (CDC) reported the 
unexplained occurrence of pneumocystis carinii pneumonia in five previously 
healthy homosexual men in Los Angels and of Kaposi’s Sarcoma in 26 
previously healthy homosexual men in New York and Los Angeles. 
In 1983, Human Immunodeficiency Virus was isolated from a patient 
with lymphadenopathy, and by 1984 it was demonstrated clearly to be the 
causative agent of AIDS. By 1994, a million cases had been reported to the 
World Health Organization (WHO) and the pandemic has now affected all 
continents. 
 
 At the end of 2006, according to Joint United Nations Programme on 
HIV/AIDS, 45.3 million people are estimated to be living with HIV/AIDS  
(41.5 million adults and 3.8 million children below 15yrs). Out of which 90% 
of cases are in the economically productive age group of 15-45 yrs. 
 
 Since the beginning of the epidemic, there have been as estimated 25 
million deaths due to AIDS. Women are becoming increasingly affected by  
HIV. Approximately 40% or 15 million of the 37.2 million adults living with 
HIV/AIDS  world wide are women. 
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Once in every three children orphaned by HIV/AIDS is under age five. 
Since the beginning of the global pandemic, over 13 million under the age of 15 
have lost their parents to HIV/AIDS. 
 
DEFINITION AND CLASSIFICATION OF AIDS 
Expanded WHO Case Definition for AIDS. 
 An adult or adolescent (>12yrs of age) is considered to have AIDS if a 
test for HIV antibody gives a positive result and one or more of the following 
conditions are present. 
• >10% of body weight loss or cachexia with chronic diarrhea or 
chronic fever or both intermittent or continuous for at least one 
month. 
• Cryptococcal meningitis 
• Pulmonary or extrapulmonary tuberculosis 
• Kaposi’s sarcoma 
• Candidiasis of oesophagus. 
• Clinically diagnosed life threatening or recurrent episodes of 
pneumonia with or without etiological confirmation. 
• Invasive cervical cancer. 
• Pneumocystis carinii pneumonia 
• Disseminated  M.avium infection 
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• CMV disease 
• HIV associated dementia 
• Toxoplasmosis 
• Immunoblastic lymphoma 
• Chronic cryptosporidiosis 
• Disseminated histoplasmosis 
WHO clinical staging system for HIV infection. 
Stage I: 
 Only a small number of people have a recognizable acute illness at the 
time of infection with the virus and most are unaware. Initially HIV infection is 
clinically silent or  asymptomatic. Very few patients may develop mild viral 
fever like illness. 
Stage II: 
 As immunosuppression develops, the CD4 count falls and viral load 
increases, there is increasing susceptibility to a small range of clinical illnesses. 
Clinical manifestation may consist of mild weight loss, skin and oral problems 
recurrent sinusitis or herpes zoster. 
 
 
 
 
               7 
Stage III: 
 With further immunosuppression, the susceptibility widens to select 
group of common and more virulent infection such as TB and bacterial 
pneumonia. Common symptoms in this stage are weight loss more than 10%, 
chronic diarrhea and prolonged unexplained fever. 
Stage IV: 
 With more profound immunosuppression, when the CD4+ T lymphocyte 
count falls below 200, the opportunistic infections develop and the individuals 
considered to have advanced disease. 
 
Disease Progression and Survival: 
 Disease progression and survival with HIV is variable such as  
Rapid Progressors, Slow Progressors and Non Progressors. It may be rapidly 
progressive over 2yrs or hardly progresses at all over 15 yrs. However older age 
and low socio-economic status adversely affect survival. 
 
VIROLOGY – HUMAN IMMUNODEFICIENCY VIRUS 
 HIV belongs to lentivirus subgroup of the family retroviridae. First 
identified as Lymphadenopathy Associated Virus (LAV), renamed as Human T 
cell Lymphotrophic Virus III (HTLV – III). In 1986 International committee 
on virus nomenclature decided this new generic name Human 
Immunodeficiency Virus (HIV). 
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 There are two types of HIV, type 1 and 2. Type 1 is more virulent 
pathogen than type 2 and seen worldwide. HIV 1 and 2 are each approximately 
100nm in diameter and have a single stranded RNA genome. The virion has a 
cylindrical nucleo capsid that contains the single stranded RNA and viral 
enzymes including proteinase, integrase and reverse transcriptase. Enzyme 
reverse transcriptase is the characteristic feature of retrovirus. Surrounding the 
capsid is a lipid envelope that is derived from the infected host cell and that 
contains three structural genes; gag, pol and env. HIV 1 and HIV 2 are 
genetically similar in the gag and pol regions. The env regions are however 
different. This variation results in differences in the envelope glycoproteins of 
these viruses. Such heterogenicity leads to specific immune responses to these 
viruses, which necessitates different immune assays or western blot procedures 
for serologic diagnosis of HIV 1 and HIV 2. In addition to the three structural 
genes, HIV contains six additional regulatory genes, tat, rev, vif, vpr, ref and 
vpu. Of these, two (tat and rev) are essential for viral replication. HIV isolates 
show marked heterogenicity in the env and the ref genes, which results in 
differing tissue and cell tropism, variation in pathogenesis, disparable responses 
to therapy and potential challenges to develop a broadly cross reactive 
protective vaccine. 
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TRANSMISSION 
   Four principle modes of transmission of the virus are recognized. 
(i) Sexual intercourse – vaginal or anal intercourse in either heterosexual 
or homosexual. 
(ii) Transfusion of infected blood. 
(iii) Use of contaminated needles or syringes. 
(iv) Vertical – From an infected mother to her baby. 
 
Mode of Transmission of  HIV infection: 
 
Type of  Exposure Efficiency in single 
exposure 
% of Total 
Transmission 
Blood transfusion >90% 3-5% 
Perinatal 30% 5-10% 
Heterosexual 0.1 – 1.0 % 60-70% 
Homosexual 0.1 -1.0% 5-10% 
IV Drug abuse 0.5 – 1.0% 5-10% 
Health Care <0.5% <0.1% 
 
Although the efficacy of sexual mode of transmission is low, it accounts 
for the commonest mode of transmission because of the absolute number of risk 
intercourse is heavy. 
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PATHOGENESIS 
 Initial events in HIV infection include attachment of the virus to a 
distinct group of T cells and monocytes / macrophages that display a membrane 
antigen complex known as CD4. After attachment, the lipid membrane of the 
virus fuses with the target cell, thereby allowing entry of the viral core into the 
host cell cytoplasm. This viral core is subsequently uncoated and transcribed by 
the reverse transcriptase enzyme which results in a complementary strand of 
DNA. This DNA then becomes double stranded by the action of cellular 
enzymes,  subsequently becomes circular and enters into the cell nucleus, where 
integration into the host cellular genome takes place by means of a viral 
endonuclease. The actively infected cell produces many virions by transcription 
of proviral DNA. The transcription also generates messenger RNA, which in 
the cytoplasm is translated into HIV specific structural proteins, that are 
integrated with the core particles. Final maturation of the virus occurs by a 
process of reverse endocytosis (budding) at the plasma membrane and 
susbsequent dissemination occurs. 
 
The initial target cells of HIV, namely CD4+T helper cells and  
macrophages, show different cytopathic effects. The T cells gradually decrease 
in number from the virus replication leading to immunodeficiency and 
subsequent secondary opportunistic infections. In contrast, the infected  
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macrophages, instead of undergoing lysis, harbor the virus and disseminate it 
throughout the body.  
However, their immune-related functions are altered - decreased 
migration response to chemoaltractants, defective intracellular killing of various 
micro organisms such as Toxoplasma gondii and Candida, reduced expression 
of class II molecules, which impairs the processing and presentation of antigen 
to T helper cells, and excessive production of tumour necrosis factor alpha (by 
the macrophages) which leads to dementia, wasting syndrome and unexplained 
fever. 
Disease Course 
 The illness that results from HIV infection varies from one individual to 
another with several predictable stages that leads invariably to death. In general 
infected individuals initially experience an acute primary infection, followed by 
a relatively asymptomatic infection that can include generalized 
lymphadenopathy. This progresses to symptomatic disease associated with 
progressive decline in  
T-helper cells, and eventually to advanced HIV disease with the development of 
opportunistic infections or malignancies. 
 
 The acute HIV infection lasts for about one to two weeks and is 
characterized by symptoms typical of a non specific viral illness. Patients then 
invariably enter into an asymptomatic phase that can last for two or more than  
           12 
ten years. During this phase the CD4+ T lymphocyte count varies from about 
750 to 200 cells / cu.mm (normal count being 600 to 1400 cells / cu mm). 
 
The asymptomatic phase is followed by advanced HIV disease, which 
may last for up to three years; during this stage the CD4+ T lymphocyte cells 
decrease to less than 200 cells / cu mm. 
 
DIAGNOSIS 
 
 HIV infection is diagnosed by blood tests that detect HIV antibodies. 
 
 The tests usually being done are. 
• RAPID test 
• ELISA test 
• WESTERN BLOT test 
 
RAPID and ELISA tests are sensitive, specific and less expensive. These 
are commonly used for screening purposes in blood banks and at voluntary 
counselling and testing centres. 
 
WESTERN BLOT test, though more specific, is costly. Hence it is used 
primarily to confirm the screening test results which turned out positive. 
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Diagnosis can also be made by testing for HIV antigens through. 
• Polymerase Chain Reaction (PCR) test 
• Viral load assessment tests like NASBA 
• P24 Antigen test 
The first two tests become positive after 72 hours of infection and the 
third one becomes positive after 2 weeks of  infection. 
 
Indirect Immunofluorescent Assay (IFA), Radio Immuno Precipitation 
Assay (RIPA), Passive haemagglutination assay and Dot immunobinding assay 
also are available. 
 
THERAPY 
 In the management of HIV infection, the prevention of complication 
involves not only anti retroviral therapy and prophylactic antimicrobials, but 
also immunization (e.g. HBV, Influenza vaccines and in specific cases other 
available vaccines) and early disease detection. 
 
 Anti-retroviral drugs in current use belong to four classes: 
• Nucleoside Reverse Transcriptase Inhibitors (NRTI’S) 
• Non Nucleoside Reverse Transcriptase Inhibitors (NNRTI’S)  
• Protease Inhibitors (PI’s)              and  
• Fusion / Entry Inhibitors.  
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NRTI’S and NNRTI’S inhibit reverse transcriptase and this prevents the 
virus from infecting the cell. PI’s inhibit protease, an enzyme which cleaves 
viral proteins and is important for the final assembly of virions. PI’s are the 
most potent anti-retroviral drugs. Fusion / Entry inhibitors represent the new 
class of anti-retrovirals. This injectable drugs inhibit HIV fusion with the CD4 
cell membrane and is intended for use in patients who have failed with other 
regimens. 
 
NRTI NNRTI PI FUSION/ENTRY
INHIBITORS 
Zidovudine 
Didanosine 
Stavudine 
 
Lamivudine 
Zalcitabine 
Abacavir 
Tenofovir 
 
 
Delvaridine 
Nevirapine 
Efavirenz 
Indinavir 
Ritonavir 
Nelfinavir 
 
Lopinavir 
Saquinavir 
Amprenavir 
 
 
 
Enfuvirtide 
 
 
 
Viral replication occurs at the rate of about 1010 virions per day. No 
single drug is able to inhibit this degree of viral replication. Therefore when a 
patient is exposed to one or a combination of two drugs, the continuing viral 
replication allows drug resistant mutants to develop.  
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The recommended regimens consist of  
 
• 2 NRTI’S + 1 NNRTI 
• 2 NRTI’S + 1 PI 
• 3 NRTI’S  
• 2 NRTI’S + PI Boosting (2 PI’S) 
 
CD4+ T LYMPHOCYTE COUNT AS A PREDICTOR OF RISK 
 
For years, the CD4+ T Lymphocyte count proved a reliable predictor of 
the risk of ocular complications of HIV infection. Recently, however the use of 
Highly Active Anti Retroviral Therapy (HAART) has allowed substantial and 
sustained albeit incomplete, repopulation of T lymphocytes to occur in many 
patients. Such observations have raised the question of whether reconstituted 
T lymphocyte populations are in fact functional, and more specifically, whether 
the current or the lowest CD4+ T Lymphocyte count is a better predictor of the 
risk of HIV associated disorders. 
  
 Even then the CD4+ T lymphocyte count reflects the immune status of 
the patients. Low CD4+ T lymphocyte count indicates the poor immune system. 
This alarms the physician to look for asymptomatic opportunistic infections 
which are known to occur in these patients. Absolute Lymphocyte Count 
(ALC), CD8+ T lymphocyte count, and the ratios among all these also reflects 
the immune status of the HIV patients. Serial evaluation of these counts are 
                      16 
necessary in all these patients to assess the  course of disease and to know the  
effect of treatment. 
 
CD4+ T Lymphocyte count 
 
Disorders 
< 500 cells / cu.mm Kaposi’s sarcoma  
Lymphomas 
<250 cells / cu.mm Pneumocystosis  
Toxoplasmosis  
Herpes Zoster Ophthalmicus 
< 100 cells / cu.mm Retinal or conjunctival microvasculopathy 
CMV retinitis 
Keratoconjunctivitis sicca 
Cryptococcosis 
Microsporidiosis 
HIV encephalopathy 
Progressive multifocal  encephalopathy 
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OPHTHALMIC MANIFESTATIONS OF HIV DISEASE 
 
 Numerous studies reported that around 40-70% of AIDS patients have 
ophthalmic manifestations. These lesions are divided into four groups. 
 
• Adnexal lesions 
• Anterior segment lesions 
• Posterior segment lesions 
• Neuro - ophthalmic lesions 
 
Adnexal lesions: 
 
• Herpes Zoster Ophthalmicus 
• Kaposi’s Sarcoma of Lids and Conjunctiva 
• Molluscum Contagiosum of Lid 
• Squamous Cell Carcinoma 
• Burkitt’s Lymphoma 
• Orbital Cellulitis 
 
Anterior segment lesions 
 
• Dry eyes 
• Conjunctival microvasculopathy 
• Infectious Keratitis 
• Anterior Uveitis 
• IRU – Immune Reconstitution Uveitis. 
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Posterior segment lesions 
 
• HIV Retinopathy 
• CMV Retinitis 
• Toxoplasma Retinochoroiditis 
• Pneumocystis Choroiditis 
• Acute Retinal Necrosis 
• Progressive Outer Retinal Necrosis 
• Endogenous Endophthalmitis 
• Bacterial and Mycobacterial Retinitis 
 
Neuro Ophthal Lesions: 
 
• Cranial Nerve Palsies 
• Papilloedema 
• Papillitis 
• Optic Atrophy 
 
Herpes Zoster Ophthalmicus. 
 
 HZO presents as painful vesiculobullous dermatitis, results from the 
reactivation of previously established primary VZV infection. This virus lies 
dormant in dorsal root ganglion of any sensory nerve and HZO is due to 
reactivation in the trigerminal nerve ganglion commonly affecting the 
ophthalmic division of this cranial nerve. This is uncommon in less than 50  
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years age and is common in young male homosexuals who are immuno -
compromised due to HIV infection. The severity of disease is more in HIV 
patients than normal immunocompetent patients. 5-15% patients will develop 
sight threatening complications like Conjunctivitis, Keratitis, Uveitis, and 
Retinitis. 
 
 It is treated with IV Acyclovir 10mg/kg body weight thrice daily for 
seven days followed by Oral Acyclovir 800mg 5 times / day. 
 
Kaposi’s Sarcoma: 
 
 This is highly vascularised painless mesenchymal tumour affecting the 
skin and mucous membrane in 25% of HIV Patients. 20% patients have 
asymptomatic Kaposi’s Sarcoma of eyelids or conjunctiva. This may be missed 
if fornices are not examined properly. It presents as nodules or polypoidal 
growth. It may be mimicking as chalazion or subconjunctival haemorrhage. 
Kaposi’s sarcoma should be suspected when a HIV patient is having persistent 
SCH. 
 
 Treatment is with radiation, cryotherapy and intralesional chemotherapy 
with vinblastin, ά–interferon and liposomal daunorubin are also used. In spite of 
all these modalities of treatment, 100% recurrence is noted in some studies. 
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Molluscum Contagiosum:  
This is more frequent and severe in patients, who are HIV +ve than who 
are negative for HIV. It is an infection of skin and mucous membrane caused by 
DNA Pox Virus, involving face and upper body. Usually presents as multiple 
small painless umbilicated nodules of 2-10mm diameter. 
 
Pressure over the lesion will produce waxy discharge. This may even 
spread to bulbar conjunctiva.  
 
 Treatment is with cryotherapy, curettage, excision therapy or 
electrocautery. Podophyllotoxin cream also is used as adjunct to cryotherapy. 
 
Squamous Cell Carcinoma: 
 
 Human Pox Virus or P53 gene over expression may play a role in the 
development of this tumour in patients who are infected with HIV. Treatment is 
Excision, Enucleation or Excentration, depends on the extension of disease at 
the time of presentation. 
 
Burkitt’s Lymphoma: 
 
 In patients who are having systemic Non-Hodgkin’s Lymphoma either on 
treatment or in tumour remission develops lymphomatous infiltration of optic 
nerve and occlusion of central retinal vein. There is dense infiltration of optic 
nerve and necrotizing vasculitis involving retinal vessels near optic nerve. 
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Orbital Cellulitis: 
 
 HIV patients may develop orbital cellulitis because of their immuno-
compromised status. Aspergillus species and Mucor mycosis are the common 
etiological agents causing cellulitis. Patients present with swollen lids, 
erythema, pain, congestion of conjunctiva, proptosis, restriction of movements 
with defective vision. Treatment is by systemic antibiotics, antifungals and 
supportive measures. 
 
Dry Eyes: 
 
 20% of HIV patients develop dry eyes in later stages of illness. This is 
due to HIV mediated inflammation and damage to major and accessory lacrimal 
glands. Complaints are red eye, watering, burning and FB sensation. Corneal 
ulcers may develop as complication. Schirmer’s test and Fluoresin dye test are 
used to assess the severity. Artificial tears containing methyl cellulose are 
prescribed. 
 
Conjunctival Microvasculopathy: 
 
 70-80% of HIV patients have asymptomatic conjunctival microvascular 
changes. The changes are segmental vascular dilatation, narrowing, micro-
aneurysm formation, appearance of comma shaped vascular fragments and 
sludging of blood columns. Increased plasma viscosity, and immune complex  
deposition are considered to be the pathological event. Direct infestation of 
conjunctival vascular endothelium by the virus also is suggested.  
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Infectious Keratitis: 
 
 VZV and HZV are the most common etiological agents. Painful corneal 
ulceration with characteristic dendritic or branching pattern is noted. Treatment 
is with oral acyclovir or famciclovir. Long term therapy is needed. 
 
 Bacterial and fungal keratitis also are noted. Staphylococcus aureus and 
Pseudomonas aeruginosa are the common causative agents. Candidal species 
are common in IV drug users. Microsporidia has also been implicated in some 
cases with superficial punctuate keratopathy. Gram stain, KOH mount are used 
to identify the organisms. Microsporidia are seen within the cornea or 
conjunctival epithelial cells with the use of either Massontrichrome or Giemsa 
staining. 
 
Iridocyclitis: 
 
 Mild Iritis and Iridocyclitis are common in HIV patients and usually 
associated with CMV retinitis or HZO. Also it is seen with Toxoplasma 
retinochoroiditis, Syphilitic retinochoroiditis, and in Tuberculous retinitis. 
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Immune Reconstitution Uveitis: 
 
 IRU syndrome can occur in patients with advanced HIV disease soon 
after initiation of effective HAART therapy, leading to exacerbation of 
previously treated opportunistic infection or new presentation of a previously 
sub clinical uveitis, when the CD4+T lymphocyte counts increasing to >100 
cells / cu.mm from the previously low levels. Otherwise Cidofovir and 
Rifabutin also can cause uveitis. 
 
 Long term complications of IRU include cataract, vitritis, papillitis, optic 
disc new vessels or optic atrophy, cystoid macular oedema and vitreous 
haemorrhage. 
 
HIV Retinopathy: 
 
 Like microvasculopathy in conjunctiva, retina also is affected by HIV 
retinopathy. The pathology is same as in conjunctiva like increased viscosity, 
immune complex deposition and direct cytopathic effect of virus on retinal 
vascular endothelium. All these things lead on to interruption of axoplasmic 
flow which manifests as Cotton Wool Spots. Microaneurysm, Retinal 
haemorrhages, telengiectasias and capillary nonperfusion also are seen. 
Exudates are not seen, differentiating this from CMV retinitis. Commonly these 
findings are seen when the CD4+T lympocyte count falls below 100 cells / 
cu.mm. These changes are usually asymptomatic and not vision threatening.  
 
 24 
But these changes may lead to progressive optic atrophy, with loss of color 
vision, contrast sensitivity and visual field defects. 
 
 Fluorescein angiography shows microaneurysm, blocked fluorescence 
(in the areas of CWS), telengieclasias and focal areas of non perfusion and 
capillary loss. 
 
CMV Retinitis: 
 
 40-60% of patients with HIV infection show features of CMV retinitis in 
various studies. This is the most common opportunistic infection and the main 
cause of blindness in AIDS patients. 
 
 
 Usually the patient’s CD4+T lymphocyte count is in between 50-100 
cells/ cu.mm, when they are affected by CMV retinitis. It is rare when the 
CD4+T lymphocyte count is >100 cells / cu.mm. CMV retinopathy may be the 
first ocular manifestation in more patients and usually patients will develop this 
within the first 7 years of the disease. 
 
 Cytomegalovirus is a DNA virus is Herpes group. There is viral invasion 
of retinal cells lead to necrosis of retina. The patients complain of reduced 
vision, floaters, blurred vision, loss of peripheral field or blind spots. 
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 There are two different features seen in CMV retinitis. The common one 
is described as “ pizza pie” appearance characterized by confluent yellow white 
areas of necrosis and predominance of hemorrhage. There is full thickness 
necrotizing retinitis. This lesion commonly found in the posterior pole adjacent 
to the blood vessels. The second pattern is “ Indolent granular retinitis” also 
called “brush fire” pattern. There is large central clearance appearing as retinal 
atrophy with a peripheral white granular border, little or no haemorrhages and 
no vasculitis. These are commonly seen in retinal periphery. The lesser 
common one is “frosted branch angitis” type to describe extensive vascular 
sheathing. There is associated perivasculitis, vascular attenuation and vessel 
closure. 
 
 Progression is usually slow along active border and along blood vessels. 
These lesions have the tendency to enlarge and coalesce over time. Retina 
behind the active edge of retinitis became pale and atrophic. Necrotic retina is 
prone to develop breaks and subsequently develop rhegmatogenous RD if 
peripheral retina is involved. Secondary neovascular glaucoma may occur in 
CMV retinitis. 
 
Fluorescein Angiography shows hyperfluoresence starts at centre and 
spreads to periphery. These areas are smaller than gross lesions. 
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The main drugs for CMV retinitis are Ganciclovir, Foscarnet and 
Cidofovir. All these are virostatic, not virocidal. Ganciclovir is a cyclic 
nucleoside, dihydroxy propoxy methyl guanine. 
               
Ganciclovir is started in induction phase as 10mg/kg bodyweight daily in 
two divided doses given IV for 2-3 weeks, followed by maintenance dose of 
5mg/kg bodyweight daily indefinitely. 
 
Intravitreal Gancyclovir injection also is given as 200mg in 0.1cc once 
weekly. Intravitreal Ganciclovir implant is commonly used nowadays to avoid 
systemic complications of the drug. It is inserted via parsplana and sutured to 
sclera. In this method, vitreal concentration of the drug is two fold more than 
IV route. Implants deliver the drug slowly for 6-7 months. But it does not give 
protection against systemic CMV infection or infection in the fellow eye. 
 
Alternatively IV Foscarnet is given 60mg/kg 8hrly for 3 weeks then in 
daily dosage. IV cidofovir in the dosage of 5mg/kg once weekly for 2 doses 
then every 2 weeks also is given. Both these drugs can also be given through 
intravitreal route. 
 
Cidofovir and Ganciclovir causes nephrotoxicity and bone marrow 
toxicity. Foscarnet is toxic to liver. 
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Recent studies suggest that anti CMV treatment may be stopped if CD4+ 
T lymphocyte count is raised more than 100-150 cells / cu.mm. for 3-6 months 
with suppression of viral load. 
Ganciclovir is good in preserving the vision. But if the lesions involve 
macula or ONH at presentation, the visual progrosis is poor. 
 
Toxoplasma Retinochoroiditis: 
 
 This can be seen in CD4+T lymphocyte count <250 cells / cu.mm but 
usually the CD4+ count is <100 cells / cu.mm. The bradyzoites of Toxoplasma 
gondii are transformed into tachyzoites that allows infiltration of retina and 
choroids leads to retinochoroiditis. 
 
 Retinal findings are single or multifocal, discrete or diffuse areas of 
necrosis. This is bilateral in 30-50%. Retinochoroiditis is due to acquired  
infection rather than reactivation. There is more vitritis. There may be 
associated intracranial lesions in some patients. 
 
 Fluorescein angiography shows hyperfluoresence starts at periphery 
and spreads to centre and the fluorescent area is larger than the gross lesion. 
 
 Both IgG and IgM antibody levels are raised, however in very 
immunocompromised patients these tests may be negative. 
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 Treatment is with Sulphadiazine, Clindamycin, Pyrimethamine and 
Folinic acid. Folinic acid is given to counter macrocytic anemia induced by 
Pyrimethamine. 
Acute Retinal Necrosis (ARN) 
 
 This is due to VZV, HSV or CMV. In HIV patients with HZO, 17% 
develop ARN and in 30% it is bilateral. It presents as one or more foci of retinal 
necrosis with discrete borders and is located in peripheral retina, described as 
“swiss cheese” pattern. There is prominent inflammation in anterior and 
posterior chamber and an occlusive vasculitis involves arterioles. Holes may 
develop later in the necrotizing areas of retina leading to RD. Treatment is with 
IV Acyclovir or Famciclovir combined with laser treatment to the posterior 
margins of necrotic areas to prevent RD. Final outcome is hampered by retinitis 
involving macula and optic atrophy. 
 
Progressive Outer Retinal Necrosis (PORN) 
 
 It is a devastating viral retinitis due to VZV. Occurrence of PORN 
usually relates to recent herpetic infection with low CD4 counts. There is 
sudden reduction in vision. Retinitis is typically multifocal, posterior and 
involves deeper layers of retina. Inflammatory signs are absent. Multiple white 
plaqnes near posterior retinal pole progress rapidly to necrosis leading to retinal 
detachment. There is no effective treatment and visual prognosis is poor.   
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 In patients with PORN, 66% become blind in 6 weeks of diagnosis despite 
aggressive treatment. Acyclovir or Ganciclovir may be tried. 
                              
Pneumocystis Choroiditis: 
 
 Pneumocystis carinii pneumonia is one of the AIDS defining 
opportunistic infection. It is an unicellular protozoan spreads via blood stream 
to choroid, commonly from respiratory system. Pneumocystis choroiditis is 
characterized by multiple yellow white subretinal deposits throughout the 
posterior pole. Visual symptoms are less as there is no vitritis.  
Fluorescein study reveals early hyperfluorescence with late staining. 
Treatment is with IV Trimethoprim with Sulphamethoxazole or IV 
Pentamidine. 
 
Fungal Chorioretinitis: 
 
 
 Common agents are Histoplasma and Cryptococcus. Usually there is 
haematogenous spread from pulmonary system or may be as direct extension 
from CNS involvement. Fundus shows multiple yellowish white mildly 
elevated chorioretinal lesions. These may progress to fungal endophthalmitis. 
 
Bacterial and Mycobacterial retinitis: 
 
 Syphitis, and M. avium intercellulare infection have been demonstrated 
in autopsies of some patients with disseminated infection. 
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Neuro ophthal Manifestation: 
 
 Neuro ophthal complications occur in 15-20% patients with HIV 
infection. Commonly presents as papilloedema, papillitis, cranial nerve palsies, 
AION and optic atrophy. 
 50% of neuro ophthal lesions are due to Cryptococcal meningitis. 
Common presentation is papilloedema bilaterally with associated signs of 
meningitis. Cranial nerve palsies are reported in 33% cases. III N is commonly 
affected followed by IV and VI nerves. Common complaint is diplopia. 
 
Causes of raised intracranial tension in HIV are NHL, Toxoplasma 
encephalitis, Cryptococcal meningitis, and metastasis commonly from Kaposi’s 
sarcoma. 
 AION is noted in advanced HIV cases. 
 
 Neurosyphilis, Toxoplasmosis are reported to cause neuro ophthal 
manifestations. Neurosyphilis run a more rapid and aggressive course in HIV 
patients than other immunocompetent patients.  
 
 Diffuse encephalopathy may be due to direct effect of virus (HIV 
encephalopathy) or super infection from polyoma virus causing progressive 
multifocal leuco encephalopathy. 
 
 
 
 Optic nerve may be damaged by infarction or direct infiltration by  
HIV virus. 
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AIM OF THE STUDY 
 
 
• To evaluate the various ophthalmic manifestations in proven HIV 
seropositive patients and document findings 
• To find out the correlation between the CD4+ T lymphocyte count of 
HIV seropositive patients and the nature and severity of the ophthalmic 
manifestations. 
• To study the variations in presentation of ophthalmic manifestations in 
different levels of immunosuppresion. 
• To stress the important role of the ophthalmologist in HIV patients for 
preventing the visual loss by early diagnosis and instituting appropriate 
therapy. 
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MATERIALS AND METHODS 
 
 
This clinical study was done to evaluate the various ophthalmic 
manifestations in a south Indian population of HIV infected persons and to find 
out the correlation between the CD4+ T lymphocyte count and nature and 
severity of ophthalmic manifestations.  
 
 A total of 60 HIV positive patients were studied. 
 
 The study period extended from January 2004 to December 2005. 
 
 
The HIV statuses of the patients were confirmed by ELISA method in 
laboratories of Government Hospital for Thoracic Medicine Tambaram. The 
CD4+ T lymphocyte count also were done in the same laboratories. 
 
 All the patients were proven cases of HIV seropositivity, and referred 
from GHTM with various ophthalmic complaints to the Regional Institute of 
Ophthalmology, Chennai. 
 
 
 
 
 
             
 33 
Detailed History taking and clinical examination done. 
History taking including 
• Occupation 
• Sexual Habits 
• IV Drug abuse 
• Socio economic status 
• General symptoms and duration 
• Ocular symptoms and duration 
• Relevant past history 
• Sexually transmitted diseases 
• History relates to mode of transmission 
• Time of HIV detection and presenting illness at that times. 
 
Ophthalmic evaluation includes: 
• Visual acuity – Snellen’s chart 
• Oblique examination with Torch and Loupe 
• Detailed slit lamp examination of Anterior Segment 
• Slit lamp biomicroscopy with +90 D lens 
• Detailed fundus examination – after dilatation with mydriatics – Direct 
and Indirect Ophthalmoscopy. 
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OBSERVATION AND RESULTS 
 
Total Number of Patients  : 60 
 
Age Distribution 
 
Table No: 1 
 
Age group No of patients (%) 
 
0-10 
 
 
- 
 
11-20 
 
 
1 (1.67%) 
 
21-30 
 
 
15 (25%) 
 
31-40 
 
 
35 (58.33%) 
 
41-50 
 
 
9 (15%) 
 
51-60 
 
 
- 
 
Total 
 
 
60 
 
 
Out of the 60 Patients in this study 50 patients were between 20-40 
years of age. 
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Sex Distribution 
Table: 2 
 
 
Sex 
 
 
No. of Patients 
 
Male 
 
38 (63.33%) 
 
 
Female 
 
17 (11.67%) 
 
 
Eunuchs 
 
5 (8.33%) 
 
 
Total 
 
60 
 
 
The Male and Female ratio in this study is 2.24:1 
 
 
Occupation of HIV+ Patients 
Table: 3 
 
 
Occupation 
 
No. of Patients 
 
 
Unskilled Labourers 
 
13 (21.67%) 
 
 
Drivers 
 
22 (36.67%) 
 
 
Commercial sex workers 
 
7 ( 11.67%) 
 
 
others 
 
18 (30%) 
 
 
Total 
 
60 
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SEXUAL HABITS OF PATIENTS 
 
 
Table: 4 
 
 
SEXUAL HABITS 
 
NO OF PATIENTS 
 
 
Heterosexual 
 
53 (88.33%) 
 
 
Homosexual 
 
7 (11.67%) 
 
 
Total 
 
60 
 
 
About 90% patients were Heterosexual in this study. 
 
 
SOURCE DISTRIBUTION 
 
Table: 5 
 
 
MODE OF TRANSMISSION 
 
NO OF PATIENTS 
 
 
Trans Sexual 
 
55 (91.67%) 
 
 
IV Drug abuse 
 
5 (8.33%) 
 
 
Total 
 
60 
 
 
Sexual exposure was the commonest mode of transmission in this study. 
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SYSTEMIC MANIFESTATION 
 
Table: 6 
 
 
 
SYSTEMIC MANIFESTATION* 
 
NO OF PATIENTS 
 
 
RS 
 
42(70%) 
 
 
CNS 
 
4 (6.67%) 
 
 
Skin 
 
8 (13.34%) 
 
 
ENT 
 
39 (65%) 
 
 
OTHERS 
 
17 (28.34%) 
 
 
 
* RS – Respiratory System 
      CNS- Central Nervous System 
   ENT – Ear, Nose and Throat 
 
¾ Some patients were having more than one or two systemic 
involvement.  
¾ The most common systemic illnesses in these patients were 
Pulmonary Tuberculosis, followed by Oral Candidiasis and Skin 
eruptions. 
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Ocular Symptoms 
 
Table No: 7 
 
 
 
Ocular symptoms 
 
No.of patients 
 
Percentage 
 
 
Defective vision 
 
 
55 
 
91.67% 
 
Vesicular eruptions 
 
 
3 
 
5% 
 
Floaters 
 
 
3 
 
5% 
 
Pain & redness 
 
 
6 
 
10% 
 
SCH 
 
 
1 
 
1.67% 
 
Diplopia 
 
 
4 
 
6.67% 
 
 
Ptosis 
 
 
2 
 
3.34% 
 
 
 
About 90% patients presented with defective vision ranging from 
minimal diminision of vision to profound visual loss. About 10% patients 
presented with pain and redness. Some patients had more than two symptoms.  
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Time Interval from detection of HIV to Ophthal evaluation. 
 
 
Table No: 8 
 
  
 
Duration (in months) 
 
 
No. of patients (percentage) 
 
<6 
 
 
6 (10%) 
 
7-12 
 
 
17 (28.33%) 
 
13-18 
 
 
14 (23.33%) 
 
19-24 
 
 
12 (20%) 
 
25-30 
 
 
6 (10%) 
 
> 30months 
 
 
5 (8.33%) 
 
 
 
 Most of the patients, about 80% were referred within 24 month of 
detection of HIV infection with ophthalmic symptoms. In patients who were 
seen in later stages, the symptoms were present even some months earlier and 
patients seek ophthal opinion later because of poor compliance and other social 
factors. 
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Ophthalmic Manifestations 
 
Table No: 9 
 
Orbit and Adnexa 
     Herpes zoster Ophthalmicus 
      Kaposi’s Sarcoma 
      Pthisis bulbi 
 
3 
1 
1 
 
5% 
1.67% 
1.67% 
Anterior segment 
Anterior uveitis 
Chronic Panuveitis 
Chronic Keratouveitis 
Mature Cataract 
 
 
3 
6 
2 
2 
 
5% 
10% 
3.34% 
3.34% 
Posterior Segment 
CMV Retinitis 
HIV Retinopathy 
Combined RD 
Rhegmatogenous RD 
Progressive Outer Retinal Necrosis 
Acute Retinal Necrosis 
Choroiditis 
Vitritis 
HT Retinopathy 
Neuro ophthal lesions 
Optic Atrophy 
Pappilloedema 
Nerve palsy    
 
16 
11 
2 
1 
1 
1 
2 
2 
1 
 
5 
5 
4  
 
26.67% 
18.33% 
3.34% 
1.67% 
1.67% 
1.67% 
3.34% 
3.34% 
1.67% 
 
8.33% 
8.33% 
6.67%  
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Severity of Visual loss 
 
Table No: 10 
 
 
 
Vision in diseased eye 
 
 
No. of patients (%) 
 
> 6/12 
 
 
9 (15%) 
 
6/18 – 6/60 
 
 
16 (26.67%) 
 
5/60 – 3/60 
 
 
4 (6.67%) 
 
2/60 – 1/60 
 
 
10 (16.67%) 
 
<  HM 
 
 
21 (35%) 
 
 
 
Out of 60 patients in this study about 50% of patients were having severe 
visual loss, less than 2/60 is snellen’s chart which prevents them being 
independent socially. 
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CD4+ T Lymphocyte count in HIV + patients 
 
Table No: 11 
 
 
CD4+ T cell count 
 
 
No of patients (%) 
 
< 50 cells / cu.mm 
 
 
17 (28.33%) 
 
 
51-100 cells / cu.mm 
 
 
20 (33.33%) 
 
101-150 cells / cu.mm 
 
 
12 (20%) 
 
151-200 cells / cu.mm 
 
 
1 (1.67%) 
 
201 – 250 cells / cu.mm 
 
 
3 (57%) 
 
> 250 cells / cu.mm 
 
 
7 (11.67%) 
 
 
 
About 60% of patients in this study were having CD4+ T Lymphocyte 
count less than 100 cells/ cu.mm. Another 20% of patients had CD4+ T 
Lymphocyte count in the range of 100-150 cells / cu.mm. 
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Ocular Manifestations, No. of patients and  
CD4+ T Lymphocyte count. 
Table No: 12 
 
Ocular Manifestations No. of patients CD4+ Count 
Herpes Zoster 
Ophthalmicus 
 
3 
 
200-250 cells/cu.mm 
Kaposi’s sarcoma 1 180 cells/cu.mm 
Chronic Panuveitis 6 100-150 cells/cu.mm 
Chronic Keratouveitis 2 50-100 cells / cu.mm 
 
CMV Retinitis 
(Total 16 patients) 
8 
5 
1 
2 
< 50 cells / cu.mm 
51-100 cells / cu.mm 
101-150 cells / cu.mm 
> 150 cells / cu.mm 
 
HIV retinopathy 
(Total 11 patients) 
1 
9 
1 
< 50 cells / cu.mm 
51-100 cells / cu.mm 
101-150 cells / cu.mm 
Progressive Outer 
Retinal Necrosis 
 
1 
 
29 cells / cu.mm 
Acute Retinal Necrosis 1 93 cells / cu.mm 
Choroiditis 2 < 100 cells.  
Nerve palsy 
(Total 4 patients) 
2 
2 
< 50 cells/cu.mm 
100-150 cells / cu.mm 
 
Papilloedema 
(Total 5 patients) 
2 
1 
2 
< 50 cells / cu.mm 
100-150 cells / cu.mm 
100-150 cells / cu.mm 
Optic Atrophy 5 < 50 cells / cu.mm 
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DISCUSSION 
 
 
Incidence of ophthalmic manifestations in HIV patients have been 
reported as 40%-70% in various studies. Almost all HIV patients develop 
ocular manifestations at some point of their disease period. 
This study has been directed towards various ophthalmic manifestations 
in 60 HIV seropositive patients and correlation with their CD4+T lymphocyte 
count in a Tertiary Government Hospital in South India. 
Majority of the patients in this study were in the age group of 20-40 yrs, 
which is comparable to the WHO estimate. This is the sexually active age group 
and the risk of exposure is very high. 
The sex incidence in this study was approximately 2:1. Various reports in 
2004 state that male to female ratio is nearing equal. But this ratio varies from 
region to region everywhere. In India as a whole the ratio is 3:1 and in South 
India the ratio is nearing equal. The incidence in this study can be attributed to 
various social and cultural factors. 
The mode of transmission in most of the cases is trans sexual, around 
91.67%. Rest is due to Intra Venous Drug abuse. Most common source among 
the males was contact with commercial sex workers. Most common source 
among the women was from their spouses who were HIV positive patients. 
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The time interval between detection of HIV infection and ophthalmic 
presentation is an important factor in this study. 
Most of the patients visited this hospital with visual complaints, within 
two years of detection of HIV infection. About 80% of patients developed 
ophthalmic manifestations within 24 months. Even in the patients, who were 
turned up late, they developed ocular problems much earlier and they postponed 
their ophthalmology consultation due to various social factors. 
 
The most common systemic illnesses in these patients were Pulmonary 
Tuberculosis, followed by Oral Candidiasis and Skin eruptions. 
 
Coming to ocular symptoms, most of the patients have defective vision as 
their main complaint ranging from mild defective vision to profound visual 
loss. Most of the patients had floaters and flashes with mild loss of vision in the 
earlier stages and they ignored these symptoms and landed up as visually 
handicapped within few months. 
 
Pain and redness were the main complaints in patients with anterior 
Uveitis, Panuveitis and Chronic Keratouveitis. 
 
Out of 60 patients in this study posterior segment lesions comprised 
about 50% of ophthalmic manifestations. Most common manifestation is CMV 
Retinitis in 16 patients (26.67%). Next one is HIV retinopathy in 11 patients  
(18.33%). 
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CMV Retinopathy presents as either “Pizza pie “ appearance in most 
patients and “ Frosted branch angitis” in some patients. 
 
 These lesions are evaluated by direct and indirect ophthalmoscopy. 
According to literature, diagnosis of CMV Retinitis is mainly clinical. 
Serological investigations are of limited valve and they are available in few 
laboratories only. 
 
 The incidence of posterior segment lesions in this study is comparable 
with the incidence cited in various studies Internationally. 
 
 Eight patients with CMV retinitis had CD4+T Lymphocyte count  
<50 cells / cu.mm and 5 patients had CD4+ T Lymphocyte count in the range of 
50-100 cells / cu.mm which is comparable to WHO reports and various studies.  
Three patients had CD4+ T Lymphocyte count > 100 cells / cu.mm which may 
be attributed to the effect of “HAART” therapy, they are undergoing. Most of 
the patients with CMV retinitis have very poor vision in the range of 6/60 to No 
Perception of Light. 
 
 HIV retinopathy also is evaluated ophthalmocopically. Eleven patients in 
this study had HIV retinopathy and their CD4+ T Lymphocyte count is less than 
100 cells / cu.mm in 10 patients. These patients preserve their vision at the time 
of presentation, better than 6/36 in most patients. 
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Two patients had active choriditis lesions. Their antibody levels for 
Toxoplama were negative. Literature and various studies reveal that antibody 
titre may be negative due to their immunocompromised state. 
 
 Progressive Outer Retinal Necrosis and Acute Retinal Necrosis were seen 
in one patient each.  
Combined Retinal Detachment with both Rhegmatogenous and 
Tractional components seen in 2 patients most probably due to complication of 
any posterior segment lesions of HIV diseases. 
 
 Chronic panuveitis was noted in 6 patients and anterior uveitis in 3 
patients. All these patients have CD4+ T Lymphocyte count within the range of 
100-150 cells / cu.mm. 
 
 Three patients had Herpes Zoster Ophthalmicus and their CD4+ T 
Lymphocyte count is in the range of 200-250 cells / cu.mm. One patient with 
Herpes Zoster Ophthalmicus developed panophthalmitis in one eye and the eye 
became pthisical within two months of the onset of disease since the patients 
did not seek proper treatment in time. 
 
 One patient had suspected Kaposi’s sarcoma in the form of persistent 
subconjunctival haemorrhage. 
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 Five patients had papilloedema of both eyes of which 3 patients were 
having Cryptococcal meningitis proved by lumbar puncture. Two patients had 
raised intracranial tension with diffuse cerebral cortical atrophy noted in 
Computed Tomography. All five patients had CD4+ T Lymphocyte count < 150 
cells / cu.mm. 
 
 Four patients had Nerve palsies in the form of restricted eye movements 
and Optic atrophy seen in 5 patients, most probably due to complications of 
posterior segment lesions evidenced by CMV retinitis changes in posterior pole. 
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SUMMARY 
 
 
• This clinical study was done at Regional Institute of Ophthalmology, 
Chennai 
• A total of 60 patients who are HIV positive were evaluated, out of that 40 
were males and 20 were females. 
• Relevant data were collected from each patient and they were subjected 
to a detailed ophthalmic evaluation. 
• 83% belong to the age group of 20-40 years. 
• Mode of transmission in most of the patients is Trans sexual, the rest 
were due to IVD abuse. 
• Most of the patients developed ophthalmic complications within 2 years 
of detection of HIV infection. 
• More than 60% of patients were severely affected with the visual activity 
of less than <6/60. 
• More than 50% patients had posterior segment lesions of which the most 
common manifestation is CMV retinitis followed by HIV retinopathy. 
• Most of the patients with posterior segment lesions had CD4+ T 
Lymphocyte count < 100 cells / cu.mm 
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• Anterior uveitis and Chronic panuveitis were noted in 15% of patients 
and CD4+ T Lymphocyte count in these patients is in the range of 100-
150 cells / cu.mm . 
• 5% patients had Cryptococcal meningitis  
• 6.67% patients had Nerve palsies 
• 8.33% patients had Optic atrophy. 
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CONCLUSION 
 
 
• Ophthalmic manifestations of HIV are increasingly being recognized and 
the role of an ophthalmologist in its diagnosis. 
• Fundus changes are one of the most important ocular manifestations of 
HIV and can serve as an early indicator for the detection and assessment 
of progression of disease. 
• Routine ophthalmological evaluation should form a part of the clinical 
examination of all HIV seropositive patients. 
• Regular evaluation of CD4+ T Lymphocyte count combined with 
ophthalmological examination may detect ophthalmic lesions early so 
that treatment may be started without delay. 
• Periodic ophthalmic evaluation in high risk groups like prisoners, 
commercial  sex workers, truck drivers and homosexuals should become 
mandatory in routine health examination for early detection of AIDS 
through ophthalmic examination. 
• Mass education of the public and increasing their awareness on safe 
sexual practices, safety precautions during Intravenous injections and 
Blood transfusions would go a long way in preventing this devastating 
illness as we all know, PREVENTION IS BETTER THAN CURE. 
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KEY TO MASTER CHART 
SEX        SOURCE 
M – Male       TS – Trans Sexual 
F- Female       IVD – Intra Venous Drug 
use 
E – Eunuch 
OCCUPATION       SEXUAL HABIT 
L – Unskilled Labourers      HE – Heterosexual   
D – Driver       HO – Homosexual 
CSW – Commercial Sex         
             Workers.      V/A – Visual Activity 
O – Others       CV – Colour Vision 
    
SYSTEMIC INFECTIONS    OCULAR SYMPTOMS 
PT – Pulmonary Tuberculosis    DV – Defective Vision 
EPT – Extrapulmonary Tuberculosis   F – Floaters 
OC – Oral Candidiasis     P – Pain 
HZ – Herpes Zoster     FIELDS 
HS – Herpes Simplex     N – Normal 
GU – Genital Ulcers     NP – Not Possible   
GE – Gastro Enteritis     D – Defective 
 
OPHTHALMIC MANIFESTATIONS. 
CWS – Cotton Wool Spots    CPU – Chronic Pan Uveitis 
H – Haemorrhages      RD – Retinal Detachment 
MA – Microaneurysm     OA – Optic Atrophy 
CKU – Chronic Kerato Uveitis    V – Vitritis 
HZO – Herpes Zoster Ophthalmicus   MC – Mature Cataract 
AU – Anterior Uveitis     P – Papilloedema 
CMVR – Cytomegalo Virus Retinitis   C- Choroiditis 
CC – Complicated Cataract 
CD4  – CD4+ Tlymphocyte Count 
N.O. –  Neuro Ophthalmology 
 
 
 
 
 
 
 
 
 
 
 
CASE SHEET 
 
Name:        Age / Sex: 
 
IP/OP No:   Occupation: 
Address: 
 
General symptoms: wt loss/diarrhoea/chronic fever/chronic 
    Cough / oral ulcer/skin lesions 
Ocular complaints: defective vision / loss of vision (sudden / Gradual) 
floaters / flashes / irritation / diplopia /Pain / redness. 
Risk factors: sexual promiscuity / previous or present STD 
infection / IV drug abuse / blood transfusion/CSW 
Possible source of infection: transsexual / IV drug / blood transfusion 
Time of HIV detection:  
Treatment history: since……………..at………………………. as 
 IP / OP 
Examination: 
General: nourishment / anaemia / jaundice / clubbing 
             Gen.lymphadenopathy/pedal edema/oral candidiasis. 
Pulse:   BP: 
Systemic examination: 
CVS: 
RS: 
P/A: 
CNS: 
Associated systemic infections: GI/MC/PT/EPT/HS/HZ/GU/OC/LRI/GE. 
 
 
Ocular examination: 
   RE    LE 
Eye brows 
Eye lid 
Lacrimal system 
Conjunctiva 
Sclera 
Cornea 
AC 
Iris 
Pupil 
Lens 
SLE: normal / specific 
 Ocular kaposis / conjunctival candidiasis 
 Ocular herpes / ocular molluscum 
V/A: 
Colour vision 
Fields 
Fundus 
Direct 
IDO: 
(CMV retinitis / optic neuritis crptococcal / pneumocystic carinii chorioretinitis) 
TC:   DC:   ESR:    Hb: 
RBS:   blood urea:  VDRL: 
Serology for HIV / ELISA / TRIDOT / WB 
CD4 Count: 
Sputum  for AFB: 
Others 
Follow up: 
KEY TO MASTER CHART 
SEX        SOURCE 
M – Male       TS – Trans Sexual 
F- Female       IVD – Intra Venous Drug 
use 
E – Eunuch 
OCCUPATION       SEXUAL HABIT 
L – Unskilled Labourers      HE – Heterosexual   
D – Driver       HO – Homosexual 
CSW – Commercial Sex         
             Workers.      V/A – Visual Activity 
O – Others       CV – Colour Vision 
    
SYSTEMIC INFECTIONS    OCULAR SYMPTOMS 
PT – Pulmonary Tuberculosis    DV – Defective Vision 
EPT – Extrapulmonary Tuberculosis   F – Floaters 
OC – Oral Candidiasis     P – Pain 
HZ – Herpes Zoster     FIELDS 
HS – Herpes Simplex     N – Normal 
GU – Genital Ulcers     NP – Not Possible   
GE – Gastro Enteritis     D – Defective 
 
OPHTHALMIC MANIFESTATIONS. 
CWS – Cotton Wool Spots    CPU – Chronic Pan Uveitis 
H – Haemorrhages      RD – Retinal Detachment 
MA – Microaneurysm     OA – Optic Atrophy 
CKU – Chronic Kerato Uveitis    V – Vitritis 
HZO – Herpes Zoster Ophthalmicus   MC – Mature Cataract 
AU – Anterior Uveitis     P – Papilloedema 
CMVR – Cytomegalo Virus Retinitis   C- Choroiditis 
CC – Complicated Cataract 
CD4  – CD4+ Tlymphocyte Count 
N.O. –  Neuro Ophthalmology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIST OF OPERATIONS PERFORMED 
 
 
 
SI.No Hospital 
No 
Date Name Age/Sex Surgery 
1 379005 27/03/04 Vijayalakshmi 45/F RE  ECCE with PI 
2 381853 18/06/04 Angamuthu 65/F LE  ECCE with PCIOL 
3 386915 04/12/04 Marimuthu 45/F RE  ECCE with PCIOL
4 391184 25/04/05 Janakiammal 52/F RE  SICS with PCIOL 
5 392342 30/05/05 Kamatchi 60/F RE  SICS with PCIOL 
6 701231 17/11/05 Mangammal 67/F RE  ECCE with PCIOL 
with Trabeculectomy 
7 711201 15/12/05 Jaggamma 72/F RE  ECCE with PCIOL 
with Trabeculectomy 
8 722307 12/01/06 Lourdus 68/M RE  RD Surgery 
9 385815 17/10/04 Subbarayan 65/M RE  Therapeutic 
Keratoplasty 
10 389714 17/11/04 Senthamarai 45/F LE  Therapeutic 
Keratoplasty 
11 29713 05/05/04 Kavitha 17/F RE  Chalazion  Incision 
and Drinage 
12 48656 30/06/04 Muniamma 68/F LE  Ptergium Excision 
13 67514 01/02/05 Arumugam 65/M LE  Dacryocystectomy 
14 7940 04/02/06 Poongothai 25/F RE  Dacryo cysto 
rhinostomy 
15 27154 27/11/04 Govindhan 43/M LE  Lower lid tear 
suturing 
16 1751 06/02/05 Angamma 63/F RE  Evisceration 
17 2315 28/03/05 Pappammal 67/F RE  Tarsorrhaphy 
18 4375 20/05/05 Somu 47/M LE Corneal tear 
suturing 
19 1327 18/02/06 Madhavan 53/M RE  Corneo scleral tear 
suturing 
20 41477 20/05/05 Kesavaiah 67/M RE  Scleral tear 
suturing 
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1 Pazhani 37 M L HE TS 10 Mths GI,PT,OC,GE 6/36,6/60 DV 349 Gr.IV HT.RP N
2 Govindhan 36 M D HE TS 22 Mths PT,OC 6/18,6/18 F,DV 286 AU N
3 Padmavathy 38 F O HE TS 7 Mths OC 2/60,4/60 DV,PAIN 123 CPU,CC Tr.with Rheg.RD NP
4 Vasantha 36 F CSW HE TS 16 Mths PT,OC PL+,6/18 DV 24 CMVR, OA NP
5 Sridhar 34 M D HE TS 26 Mths OC,GE 6/12,6/9 DV 412 V N
6 Ramu 40 F O HE TS 28 Mths PT,HS,GU 1/60,PLP DV 252 MC,MC NP
7 Revathy 26 F L HE TS 9 Mths PT,OC, GU 6/12,6/18 DV 107 P(BE), VI NP N
8 Jegan 35 M D HO TS 18 Mths GE HM,6/6 DV 87 CMVR NP
9 Marimuthu 40 M O HE TS 20 Mths OC 2/60,3/60 DV 16 CC NP
10 Gandhimathi 35 F O HE TS 11 Mths PT 6/12,6/18 DV 24 AC N 
11 Paliah 16 M D HE TS 6 Mths PT,OC 6/18,6/24 DV 76 CMVR N
12 Anbazhagan 40 E CSW HO TS 38 Mths PT,OC 6/12,6/12 DV 87 CWS/MA N
13 Mallika 37 F L HE TS 8 Mths EPT 6/60,2/60 DV 74 CMVR NP
14 Madhavan 34 M D HE TS 36 Mths OC NOPL,NOPL DV 10       OA, III NP NP
15 Azhagesan 32 M O HE TS 5 Mths PT 6/6,NOPL DV 211 PTHYSIS NP
16 Anbu 24 M D HE TS 9 Mths PT,OC 6/12,1/60 DV 126 CPU NP
17 Balan 43 E CSW HO TS 8 Mths PT,OC PL+, PL+ PAIN 113 CPU,CC NP
18 Muthu 28 M L HE IVD 2 Mths PT HM,6/19 DV PAIN 89 CKU NP
19 Gangadharan 35 M D HE TS 13 Mths OC,PT PL+, PL+ DV 36 P(BE) NP
20 Ramaththa 30 F O HE TS 16 Mths PT 6/24,6/24 DV 76 CWS/MA N
21 Mohan 30 M D HE TS 24 Mths OC 6/6, CFCF DV 252 RD NP
22 Thirupathy 45 M D HE TS 48 Mths PT 6/12,6/12 DV 30 CWS/MA N
23 Malathi 42 F O HE TS 6 Mths HZ,OC HM, 6/12 DV 45 CMVR OA NP
24 Ekeswaran 40 M D HO TS 7 Mths EPT,OC 6/18,6/12 DV 9 CMVR N
25 Subani 32 M D HE TS 11 Mths OC,PT NO PL, HM DV 27 CMVR OA NP
26 Selvi 31 F L HE TS 14 Mths PT 6/60,6/60 VESICLES 29 PDRN N
27 Nagarajan 38 M D HE TS 15 Mths OC 6/18,6/12 DV 267 HZO N
28 Yasodha 24 F O HE TS 18 Mths PT,OC 6/12,6/24 DV 87 CWS/MA N
29 Krishnan 43 M O HE TS 22 Mths HZ,OC 6/12,6/18 DV 67 CWS/MA N
30 Kumar 35 M D HE TS 9 Mths OC 2/60,3/60 DV 112 CMVR NP
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31 Rajan 37 M L HE IVD 13 Mths PT,OC 3/60,1/60 DV 93 ARN NP
32 Selvam 32 M O HE TS 16 Mths PT,OC 6/12,6/24 DV 83 CWS N
33 Leela 26 E CSW HE TS 27 Mths OC 6/9,6/12 DV 92 CWS N
34 Jebamani 28 M L HE TS 18 Mths PT 6/9,6/12 VESICLES 212 HZO N
35 Valavan 41 M O HE TS 17 Mths PT,OC 2/60,3/60 DV 40 CMVR NP
36 Kondaiah 35 M D HE TS 18 Mths PT 6/9,6/12 DV,F 73 CWS N
37 Pugalendhi 37 M L HE TS 10 Mths PT PL+,PL+ DV 26 CMVR OA NP
38 Mahendran 27 M D HE IVD 22 Mths EPT 2/60,4/60 DV 64 CMVR N
39 Dhas 24 M L HO TS 26 Mths HZ, PT 6/12,6/18 DV 107 CWS N
40 Natarajan 33 M D HE TS 20 Mths PT, OC 6/6,1/60 DV 20 CMVR NP
41 Ismail 38 M O HE TS 11 Mths PT,OC 6/24,6/24 DV 97 CWS/MA N
42 Peter 33 M O HE TS 6 Mths PT, HS PL+ PL+ DV 48 P(BE) N
43 Jayarani 28 F CSW HE TS 34 Mths OC HM 6/9 DV,PAIN 86 CKU NP
44 Vellaiammal 47 F O HE TS 9 Mths PT PL+ PL+ DV 123 CPU,CC N
45 Irudayam 31 M D HE TS 8 Mths EPT 6/12,1/60 DV 107 CPU,CC
46 Pakayaraj 32 M L HE TS 13 Mths PT, OC 6/9,6/12 SCH 180 KS NP
47 Ayyavoo 37 M D HO TS 45 Mths OC, PT NOPL,NOPL DV 20        OA,III NP N 
48 Periaswamy 46 M L HE TS 16 Mths PT 6/60,6/60 DV 87 CMVR N
49 Sadayan 35 M D HE TS 15 Mths OC 6/18,6/12 DV 74 CWS/MA N
50 Vijaya 26 E CSW HE TS 22 Mths PT, OC 6/9,6/9 PAIN 112 AU NE
51 Saroja 31 F O HE TS 27 Mths PT, OC 3/60,2/60 DV 82 CMVR
52 Rangarajan 22 M O HE IVD 12 Mths PT, OC 1/60,2/60 DV 92 C C NP
53 Chandran 34 M D HE TS 6 Mths OC. PT HM,6/6 DV 73 CMVR NP
54 Rukmani 42 F O HE TS 10 Mths PT,OC 6/12,6/9 DV 45 V NP
55 Arumugam 27 M D HE IVD 28 Mths PT 1/60,2/60 DV 212 MC MC NP
56 Kuppabai 35 F L HE TS 19 Mths PT 6/12,6/18 DV 114 P(BE) VI NP NP
57 Akilandam 37 F O HE TS 22 Mths OC PL+ 6/18 DV 24 CMVR . N
58 Indrani 29 F CSW HE TS 20 Mths PT,OC 2/60,4/60 PAIN DV 137 CPU NP
59 Kannappan 33 M D HO TS 24 Mths PT, OC 1/60,6/60 DV 274 TR.RhegRD N
60 Filomina 38 F L HE TS 12 Mths OC,PT 6/36,6/60 DV 327 CMVR NP
